YS Biopharma Highlights Interim Results Of Pivotal Phase 3 Clinical Study Of PIKA Rabies Vaccine; Says Results Indicate That The Pika Rabies Vaccine Has Successfully Met The Primary Endpoints Of The Trial
YS Biopharma Highlights Interim Results Of Pivotal Phase 3 Clinical Study Of PIKA Rabies Vaccine; Says Results Indicate That The Pika Rabies Vaccine Has Successfully Met The Primary Endpoints Of The Trial
YS Biopharma强调了PIKA狂犬病疫苗的关键性3期临床研究的中期结果；称结果表明皮卡狂犬病疫苗已成功达到试验的主要终点
YS Biopharma Highlights Interim Results Of Pivotal Phase 3 Clinical Study Of PIKA Rabies Vaccine; Says Results Indicate That The Pika Rabies Vaccine Has Successfully Met The Primary Endpoints Of The Trial
YS Biopharma强调了PIKA狂犬病疫苗的关键性3期临床研究的中期结果；称结果表明皮卡狂犬病疫苗已成功达到试验的主要终点
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。